First migraine drug to both block, tackle headaches ‘shifts paradigm’ of treatment
Most of Lilly Rockwell’s earliest childhood memories are plagued with pain-managementto the point of vomiting. Her migraine disease worsened into adulthood as she worried over the impact it would have on her career and personal life. Rockwell, 37, of Austin, Texas, joined her mother in a clinical trial for Biohaven’s Nurtec ODT (rimegepant) as a…